Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF study

Lisa Lancaster¹, Vincent Cottin^{2

3}, Murali Ramaswamy⁴, Wim A Wuyts⁵, R Gisli Jenkins⁶, Mary Beth Scholand⁷, Michael Kreuter⁸, Claudia Valenzuela⁹, Christopher J Ryerson¹⁰, Jonathan Goldin^{11

12}, Grace Hyun J Kim^{11

12}, Marzena Jurek¹³, Martin Decaris¹⁴, Annie Clark¹⁴, Scott M Turner¹³, Chris N Barnes¹⁴, Hardean E Achneck¹³, Gregory P Cosgrove¹⁴, Éric A Lefebvre¹⁴, Kevin R Flaherty¹⁵

Affiliations

¹ Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
² National Reference Centre for Rare Pulmonary Diseases (Orphalung), Louis Pradel Hospital, ERN-LUNG, Lyon, France.
³ Claude Bernard University Lyon 1, UMR754, INRAE, Lyon, France.
⁴ PulmonIx, LLC at Cone Health, Greensboro, NC, USA.
⁵ Unit for Interstitial Lung Diseases, Department of Pneumology, University Hospitals Leuven, Leuven, Belgium.
⁶ National Heart and Lung Institute, Imperial College London, London, UK.
⁷ Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah Health, Salt Lake City, UT, USA.
⁸ Pneumology Departments, Mainz Lung Center, University Medical Center and Marienhaus Clinic Mainz, Mainz, Germany.
⁹ ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain.
¹⁰ Department of Medicine and Centre for Heart Lung Innovation, University of British Columbia, VC, Canada.
¹¹ Department of Radiology, University of California, Los Angeles, CA, USA.
¹² MedQIA LLC, Los Angeles, CA, USA.
¹³ Former employee of Pliant Therapeutics, Inc., South San Francisco, CA, USA.
¹⁴ Pliant Therapeutics, Inc., South San Francisco, CA, USA.
¹⁵ University of Michigan, Ann Arbor, MI, USA.

PMID: 39512136
PMCID: PMC11544669
DOI: 10.1177/17534666241287307

Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF study

Lisa Lancaster et al. Ther Adv Respir Dis. 2024 Jan-Dec.

. 2024 Jan-Dec:18:17534666241287307.

doi: 10.1177/17534666241287307.

Authors

Affiliations

¹ Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
² National Reference Centre for Rare Pulmonary Diseases (Orphalung), Louis Pradel Hospital, ERN-LUNG, Lyon, France.
³ Claude Bernard University Lyon 1, UMR754, INRAE, Lyon, France.
⁴ PulmonIx, LLC at Cone Health, Greensboro, NC, USA.
⁵ Unit for Interstitial Lung Diseases, Department of Pneumology, University Hospitals Leuven, Leuven, Belgium.
⁶ National Heart and Lung Institute, Imperial College London, London, UK.
⁷ Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah Health, Salt Lake City, UT, USA.
⁸ Pneumology Departments, Mainz Lung Center, University Medical Center and Marienhaus Clinic Mainz, Mainz, Germany.
⁹ ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain.
¹⁰ Department of Medicine and Centre for Heart Lung Innovation, University of British Columbia, VC, Canada.
¹¹ Department of Radiology, University of California, Los Angeles, CA, USA.
¹² MedQIA LLC, Los Angeles, CA, USA.
¹³ Former employee of Pliant Therapeutics, Inc., South San Francisco, CA, USA.
¹⁴ Pliant Therapeutics, Inc., South San Francisco, CA, USA.
¹⁵ University of Michigan, Ann Arbor, MI, USA.

PMID: 39512136
PMCID: PMC11544669
DOI: 10.1177/17534666241287307

Abstract

What is this summary about?This plain language summary shares results from a clinical study called INTEGRIS-IPF that was published in the American Journal of Respiratory and Critical Care Medicine in 2024. This study looked at a medicine called bexotegrast (beck-so-teh-grast) as a possible treatment for idiopathic pulmonary fibrosis (i-dee-uh-pa-thick pul-muh-ner-ee fie-bro-sis; IPF). Bexotegrast is an investigational medicine, which means that it is being studied and has not yet been approved by the US Food and Drug Administration (FDA), for people with IPF to take as a treatment. IPF is a chronic, progressive lung disease that makes it hard to breathe and gets worse over time. There is no cure for IPF, treatment includes symptom management and consideration for the use of nintedanib or pirfenidone, which may decrease the pace of disease progression.The study compared bexotegrast to a placebo (a treatment that looks identical to the medicine but has no medicinal effect) to look at how well it works and how safe it is in treating people with IPF. Most people in the study also took one of two medicines that are already approved by the FDA for IPF, pirfenidone or nintedanib.

Keywords: IPF; efficacy; fibrotic disease; safety.

PubMed Disclaimer

Conflict of interest statement

MJ, MD, AC, ST, HA, GC, CNB, and EL were employed by Pliant Therapeutics, Inc. and own stock at the time of this analysis. LL received grants from Roche, Pliant Therapeutics Inc, Fibrogen, Boehringer Ingelheim, Novartis, Celgene, Galecto, Bristol Myers Squibb, Bridge Biotherapeutics, Horizon, CSL Behring, and NeRRe; consulting fees from DevProBiopharma, Pieries, AstraZeneca, Oxygenium, Roche, Bellerophon, Senwha, Daewoong, Daiichi Sankyo, Nashville Biosciences, Veracyte, United Therapeutics, Structure Therapeutics, Fortress Biotech, Tvardi, ureTech, and SynDevRx; honoraria from Boehringer Ingelheim, Genentech, Veracyte, and United Therapeutics; has patent pending for Aut02; participated in a Data Safety Monitoring Board or Advisory Board for DevProBiopharma, Pieris, Oxygenium, Bellerophon, Veracyte, United Therapeutics, and Aerami. WAW received grants/fees paid to their institution from Pliant Therapeutics, Inc. GJ: received grants paid to their institution from AstraZeneca, Biogen, Galecto, GSK, Nordic Bioscience, Pliant Therapeutics, Inc., and RedV; consulting fees from AstraZeneca, Brainomix, Bristol Myers Squibb, Chiesi, CohBar, Daewoong Pharmaceutical, GSK, Pliant Therapeutics, Inc., Resolution Therapeutics, and Veracyte; honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi, patientMpower, and Roche; payment for expert testimony from Pinsent Masons LLP; and participates on a DSMB/advisory board/other board for Action for Pulmonary Fibrosis, Boehringer Ingelheim, Galapagos, NuMedii, and Vicore Pharma. MK’s previous institution received grants from Boehringer Ingelheim and Roche. CV received honoraria/consulting fees from BMS, Boehringer Ingelheim, and Roche. JG is the founder of MedQIA LLC. GK is a consultant for MedQIA LLC. MR is a co-Founder of Pulmonix, LLC clinical trial services practice. VC received consulting fees from Pliant Therapeutics, Inc. MBS: received consulting and speaker fees from Boehringer Ingelheim, Genentech, Veracyte, Imvaria and United Therapeutics. CR received institutional grant from Boehringer Ingelheim; consulting fees from Boehringer Ingelheim, Pliant Therapeutics, AstraZeneca, Trevi Therapeutics and Veracyte; honoraria from Boehringer Ingelheim, Cipla and F. Hoffmann - La Roche; expert testimony fees from Boehringer Ingelheim; meeting support from Boehringer Ingelheim and Copla. KF received institutional grant from Boehringer Ingelheim; consulting fees from Arrowhead, AstraZeneca, Bellerophone, CSL Behring, Daewoong, DevPro, Dispersol, FibroGen, F. Hoffman La - Roche/Genentech, Horizon, Immunet, Insilco, Lupin, NeRRe Therapeutics, Pliant Therapeutics, Polarean, Pure Health, Pure Tech, Respivant, Shinogi, Sun Pharmaceuticals, Trevi, United Therapeutics, and Vicore; and is the Steering Committee Chair for the Pulmonary Fibrosis Foundation.

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF study

Affiliations

Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF study

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources